Structure based design, synthesis and activity studies of small hybrid molecules as HDAC and G9a dual inhibitors.
Oncotarget
; 8(38): 63187-63207, 2017 Sep 08.
Article
em En
| MEDLINE
| ID: mdl-28968981
ABSTRACT
Aberrant enzymatic activities or expression profiles of epigenetic regulations are therapeutic targets for cancers. Among these, histone 3 lysine 9 methylation (H3K9Me2) and global de-acetylation on histone proteins are associated with multiple cancer phenotypes including leukemia, prostatic carcinoma, hepatocellular carcinoma and pulmonary carcinoma. Here, we report the discovery of the first small molecule capable of acting as a dual inhibitor targeting both G9a and HDAC. Our structure based design, synthesis, and screening for the dual activity of the small molecules led to the discovery of compound 14 which displays promising inhibition of both G9a and HDAC in low micro-molar range in cell based assays.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Oncotarget
Ano de publicação:
2017
Tipo de documento:
Article